NPH16

NPH16 is an orally active PD-1/PD-L1 inhibitor with an IC50 of 24.4 nM. NPH16 can promote HepG2 cell apoptosis. NPH16 shows excellent in vivo antitumor efficacy and favorable pharmacokinetic properties. NPH16 can be used for the study of liver cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; PD-1/PD-L1

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

N#CC1=CC=CC(COC2=CC(OCC3=C(C(C4=CC(OCCOCCN5CC(CC5)O)=CC=C4)=CC=C3)C)=C(C=C2CNCCO)Cl)=C1

Molecular Formula

C39H44ClN3O6

Molecular Weight

686.24

References & Citations

[1]Yang Z, et al. Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. J Med Chem. 2025 Jun 26;68 (12) :12593-12614.